Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Efficacy and Mechanisms of Transcranial Direct Current Stimulation (tDCS) - Effects on Working Memory in Schizophrenia

27. april 2021 oppdatert av: Christian Plewnia, MD, University Hospital Tuebingen

Impairments of cognition are a core, severely disabling feature of schizophrenia leading to poor long-term outcome with no established treatment available.

Particularly impaired executive functions (e.g working memory) are frequently observed and are consistently associated with reduced activation of the dorsolateral prefrontal cortex (dlPFC). Deficits in those functions have been shown to be closely related to negative symptoms, thought disorder, and functional outcome in schizophrenia leading to the notion that frontal lobe dysfunction is crucially important in schizophrenic psychopathology.

Noninvasive brain stimulation like tDCS can enhance executive functions like working memory in healthy subjects as well as in patients. To identify the optimal parameters for this intervention in patients with schizophrenia, the investigators first test the effects of different polarities (anodal, cathodal), stimulation intensities (1mA, 2mA) and laterality (left, right) on working-memory performance (nback task) in a sham-controlled cross-over design (n=128). To elucidate mechanisms of action, oscillatory brain activity will be registered with electroencephalography (EEG).

These experiments will provide reliable data for an evidence-based development of new clinical interventions to improve treatment of cognitive deficits in patients with schizophrenia and thus enhance schizophrenia prevention and recovery.

Studieoversikt

Detaljert beskrivelse

  1. Working hypothesis:

    In patients with subacute schizophrenia, transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (dlPFC) exerts lasting beneficial effects on working-memory performance.

  2. Research question(s):

    In patients with remitted early phase schizophrenia, this research project aims at providing evidence for:

    i) immediate improvement of working-memory performance by application of tDCS to the dlPFC in patients with schizophrenia; ii) determination of the optimal stimulation polarity, dosage and localization; iii) neurophysiological mechanisms (modulation in oscillatory activity and functional connectivity) and predictors of tDCS effects; iv) modulating effect of gender on the malleability of executive functions with tDCS.

  3. Previous work of the investigators:

    The investigators have provided proof-of principle evidence for persisting improvement of cognitive planning by a polarity-specific learning-stage dependent coupling of training and stimulation. The investigators have demonstrated that working memory and deficient cognitive control can be enhanced with anodal tDCS in depression and that the effects of tDCS are modulated by genetic polymorphisms. The investigators were the first to show impaired cortical plasticity following tDCS in schizophrenia patients at different disease states. Finally, the investigators have just successfully finished the world-wide largest clinical trial investigating the efficacy of non-invasive brain stimulation (rTMS) on negative symptoms in schizophrenia (DFG 241/10-1, Falkai, Hasan).

  4. Aims and work plan:

To examine the potential of tDCS for the improvement of working memory with remitted schizophrenia the investigators are following this work plan:

I) Immediate effects on performance:

Assessment of efficacy of tDCS polarity (anodal, cathodal), dosage (1mA, 2mA) and laterality (left and right dlPFC) on working memory (adaptive n-back(6)) in patients (n=2x2x2x16=128). In a two-session cross-over design, stimulation (tDCS and sham) will be applied to the dlPFC (left or right) for 20min (during task performance).

Studietype

Intervensjonell

Registrering (Forventet)

128

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Muenchen, Tyskland
        • Rekruttering
        • LMU Muenchen, Department of Psychiatry and Psychotherapy
        • Ta kontakt med:
          • Alkomiet Hasan, MD
      • Tuebingen, Tyskland, 72076
        • Rekruttering
        • University Hospital Tuebigen, Department of Psychiatry and Psychotherapy
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 60 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • diagnosed schizophrenia (DSM-V)
  • age (18 - 60 years)
  • right handedness
  • stable medication during 1 week of treatment and 1 week before

Exclusion Criteria:

  • history of seizures
  • metal device throughout the body
  • pregnancy
  • use of anticonvulsive medication
  • use of benzodiazepines more than 1 mg of Lorazepam equivalent
  • current substance abuse (nicotine excluded)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Transcranial direct current stimulation
tDCS with varying intensity, location and polarity
Andre navn:
  • tDCS
Placebo komparator: Sham stimulation
Double blind sham stimulation with sham mode of neuroConn device
Andre navn:
  • tDCS

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change of dprime
Tidsramme: Assessment during stimulation in a n-back task at three specific timepoints during one week
dprime provides the separation between the means of the signal and the noise distributions, compared against the standard deviation of the signal plus noise distributions
Assessment during stimulation in a n-back task at three specific timepoints during one week

Sekundære resultatmål

Resultatmål
Tidsramme
Change of reaction time in n-back task
Tidsramme: Assessment during stimulation in a n-back task at three specific timepoints during one week
Assessment during stimulation in a n-back task at three specific timepoints during one week

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Christian Plewnia, Prof., MD, University Hospital Tuebingen, Department of Psychiatry and Psychotherapy

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. oktober 2015

Primær fullføring (Forventet)

1. august 2022

Studiet fullført (Forventet)

1. oktober 2022

Datoer for studieregistrering

Først innsendt

20. juni 2016

Først innsendt som oppfylte QC-kriteriene

30. juni 2016

Først lagt ut (Anslag)

6. juli 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. april 2021

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. april 2021

Sist bekreftet

1. april 2021

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 01EE1407H

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

Ubestemt

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere